Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.
Oaknin A, Ghamande SA, Kasamatsu Y, Gil-Martin M, Grau-Bejar JF, Garcia-Duran C, Sato M, Siddiqui A, Chaudhary SP, Vugmeyster Y, Hasegawa K. Oaknin A, et al. Among authors: vugmeyster y. Clin Cancer Res. 2024 Mar 1;30(5):975-983. doi: 10.1158/1078-0432.CCR-23-1829. Clin Cancer Res. 2024. PMID: 38165683 Free PMC article. Clinical Trial.
Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort.
Doi T, Fujiwara Y, Koyama T, Ikeda M, Helwig C, Watanabe M, Vugmeyster Y, Kudo M. Doi T, et al. Among authors: vugmeyster y. Oncologist. 2020 Sep;25(9):e1292-e1302. doi: 10.1634/theoncologist.2020-0249. Epub 2020 Apr 23. Oncologist. 2020. PMID: 32324927 Free PMC article. Clinical Trial.
Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial.
Loeb DM, Lee JW, Morgenstern DA, Samson Y, Uyttebroeck A, Lyu CJ, Van Damme A, Nysom K, Macy ME, Zorzi AP, Xiong J, Pollert P, Joerg I, Vugmeyster Y, Ruisi M, Kang HJ. Loeb DM, et al. Among authors: vugmeyster y. Cancer Immunol Immunother. 2022 Oct;71(10):2485-2495. doi: 10.1007/s00262-022-03159-8. Epub 2022 Mar 9. Cancer Immunol Immunother. 2022. PMID: 35262780 Free PMC article. Clinical Trial.
Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma.
Wilkins JJ, Brockhaus B, Dai H, Vugmeyster Y, White JT, Brar S, Bello CL, Neuteboom B, Wade JR, Girard P, Khandelwal A. Wilkins JJ, et al. Among authors: vugmeyster y. CPT Pharmacometrics Syst Pharmacol. 2019 Jun;8(6):415-427. doi: 10.1002/psp4.12406. Epub 2019 Apr 25. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 30980481 Free PMC article.
Evaluation of the potential for QTc prolongation with avelumab.
Vugmeyster Y, Güzel G, Hennessy M, Loos AH, Dai H. Vugmeyster Y, et al. Cancer Chemother Pharmacol. 2019 Nov;84(5):1017-1026. doi: 10.1007/s00280-019-03925-z. Epub 2019 Sep 3. Cancer Chemother Pharmacol. 2019. PMID: 31478078 Free PMC article.
51 results